Magnetic Resonance Imaging Evaluation in Patients with Linear Morphea Treated with Methotrexate and High-Dose Corticosteroid
Table 1
Efficacy of the treatment regimen.
Clinical or Paraclinical Indices
Shapiro-Wilk Test
Before treatment Median ()
After treatment Median ()
P-value
mLoSSI
Erythema
<0.001
2.00 (2.00-2.00)
1.00 (1.00-1.50)
<0.001
Skin thickness
<0.001
1.00 (1.00-2.00)
1.00 (1.00-1.50)
0.002
New lesion/lesion extension
<0.001
1.00 (1.00-1.50)
0.00 (0.00-0.00)
<0.001
LoSDI
Dermal atrophy
<0.001
2.00 (2.00-2.00)
1.00 (1.00-1.00)
<0.001
Subcutaneous atrophy
<0.001
1.00 (0.00-2.00)
1.00 (0.00-2.00)
0.014
Dyspigmentation
<0.001
2.00 (2.00-3.00)
1.00 (1.00-2.00)
<0.001
Magnetic Resonance Imaging
0.004
4.00 (3.00-6.00)
2.00 (1.00-3.00)
<0.001
LoSDI: localized scleroderma damage index; mLoSSI: modified localized skin severity index; the Wilcoxon signed-rank test was used and adjusted P-value is reported according to Benjamini and Hochberg test.
